Isotechnika receives positive scientific advice in Europe for voclosporin
Isotechnika Pharma (TSX:ISA) said it has received positive Scientific Advice from the European Medicines Agency for a proposed Phase 3 clinical trial protocol of its drug, voclosporin, after the agency...
View ArticleIsotechnika partner cleared for Phase 3 trial in China
Isotechnika’s voclosporin is a potential breakthrough drug to prevent rejection of a transplanted kidney Isotechnika Pharma (TSX:ISA) partner 3SBio (NASDAQ:SSRX) has received approval from the China’s...
View ArticleIsotechnika gets more funding for NICAM program
Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist...
View Article
More Pages to Explore .....